Status:
COMPLETED
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients
Lead Sponsor:
Third Affiliated Hospital, Sun Yat-Sen University
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Patients with HCV genotype 6 infection who have a rapid virological response to treatment are randomised to either 24 or 48 weeks HCV treatment. Our hypothesis is that there is no important difference...
Detailed Description
High rate of infection of Hepatitis C Virus(HCV) Genotype 6 was recently confirmed in Southern China. Recent study implied chronic hepatitis C genotype 6 responds better to the 48-week treatment with ...
Eligibility Criteria
Inclusion
- HCV RNA is positive
- Genotype 6
- Treatment naive
- Raised ALT
Exclusion
- Active substance abuse
- Poorly controlled psychiatric disease
- HBsAg positive
- Anti-HIV positive
- Suffering from other significant concurrent medical conditions including chronic liver diseases
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
242 Patients enrolled
Trial Details
Trial ID
NCT01263860
Start Date
December 1 2010
End Date
June 1 2014
Last Update
November 18 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
The Eighth People's Hospital of Guangzhou
Guangzhou, Guangdong, China, 510060
2
The Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630
3
Panyu People's Hospital
Guangzhou, Guangdong, China
4
Zhongshan second people's hospital
Zhongshan, Guangdong, China